Recombinant VEGFA (Brolucizumab Biosimilar) anticorps

N° du produit ABIN7795130

Cet anticorps Souris Monoclonal détecte spécifiquement VEGFA (Brolucizumab Biosimilar) dans FACS et in vivo. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Recombinant VEGFA (Brolucizumab Biosimilar) anticorps (ABIN7795130)

Antigène: VEGFA (Brolucizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-VEGFA (Brolucizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody

Attributs du produit: Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human VEGF-A

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur VEGFA (Brolucizumab Biosimilar)

Antigène: VEGFA (Brolucizumab Biosimilar)

Autre désignation: Brolucizumab Biosimilar

Classe de substances: Biosimilar